TY  - JOUR
A1  - Gerhard-Hartmann, Elena
A1  - Goergen, Helen
A1  - Bröckelmann, Paul J.
A1  - Mottok, Anja
A1  - Steinmüller, Tabea
A1  - Grund, Johanna
A1  - Zamò, Alberto
A1  - Ben-Neriah, Susana
A1  - Sasse, Stephanie
A1  - Borchmann, Sven
A1  - Fuchs, Michael
A1  - Borchmann, Peter
A1  - Reinke, Sarah
A1  - Engert, Andreas
A1  - Veldman, Johanna
A1  - Diepstra, Arjan
A1  - Klapper, Wolfram
A1  - Rosenwald, Andreas
T1  - 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
T2  - British Journal of Haematology
N2  - High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.
KW  - fluorescence in situ hybridisation
KW  - major histocompatibility complex
KW  - immune checkpoint blockade
KW  - classical Hodgkin lymphoma
KW  - CD274
Y1  - 2022
UR  - https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/25835
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-258358
VL  - 196
IS  - 1
ER  -